02565.HK
PegBio Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 5.74
+0.61%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
HKD 2.21B
MomentumView details →
1D Return
+0.61%
YTD Return
−91.69%
RSI (14)
44.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
HKD 2.21B
RSI (14)
44.7
MomentumView details →
1D Return
+0.61%
YTD Return
−91.69%
Similar companies
Latest newsMore news →
Paige Biopharmaceuticals (02565) signed a material transfer agreement with SN BioScience to apply SN BioScience's SNA long-acting drug delivery platform to three of Paige's metabolic disease peptide candidates including APGP6 for joint research.3d agoPegBio Co., Ltd. received the first commercialization cooperation payment of about HK$61 million from Tenrui Pharmaceutical under an agreement for the commercialization of Paidakang in mainland China.11d agoRani Therapeutics entered into a research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill platform.22d ago